On May 23, 2024, Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash. Wilson Sonsini Goodrich & Rosati advised Mirus Bio and Gamma Bio on patent matters related to the transaction.

Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN® GMP and RevIT™ AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.

The Wilson Sonsini team that advised Mirus Bio and Gamma Bio on patent matters related to the transaction included Ali Alemozafar, Feng Tian, and Tony Nastase.

For more information, please see Gamma Bio’s press release.